Cargando…
Doubtful clinical benefit of casirivimab-imdevimab treatment for disease severity outcome of high-risk patients with SARS-CoV-2 delta variant infection
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
European Federation of Internal Medicine. Published by Elsevier B.V.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8919793/ https://www.ncbi.nlm.nih.gov/pubmed/35300887 http://dx.doi.org/10.1016/j.ejim.2022.03.001 |
| _version_ | 1784668998804176896 |
|---|---|
| author | Shopen, Noah Dekel, Michal Mizrahi, Michal Zandberg, Efrat Talmud, Daniel Cohen, Neta |
| author_facet | Shopen, Noah Dekel, Michal Mizrahi, Michal Zandberg, Efrat Talmud, Daniel Cohen, Neta |
| author_sort | Shopen, Noah |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8919793 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | European Federation of Internal Medicine. Published by Elsevier B.V. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-89197932022-03-14 Doubtful clinical benefit of casirivimab-imdevimab treatment for disease severity outcome of high-risk patients with SARS-CoV-2 delta variant infection Shopen, Noah Dekel, Michal Mizrahi, Michal Zandberg, Efrat Talmud, Daniel Cohen, Neta Eur J Intern Med Letter to the Editor European Federation of Internal Medicine. Published by Elsevier B.V. 2022-06 2022-03-14 /pmc/articles/PMC8919793/ /pubmed/35300887 http://dx.doi.org/10.1016/j.ejim.2022.03.001 Text en © 2022 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Letter to the Editor Shopen, Noah Dekel, Michal Mizrahi, Michal Zandberg, Efrat Talmud, Daniel Cohen, Neta Doubtful clinical benefit of casirivimab-imdevimab treatment for disease severity outcome of high-risk patients with SARS-CoV-2 delta variant infection |
| title | Doubtful clinical benefit of casirivimab-imdevimab treatment for disease severity outcome of high-risk patients with SARS-CoV-2 delta variant infection |
| title_full | Doubtful clinical benefit of casirivimab-imdevimab treatment for disease severity outcome of high-risk patients with SARS-CoV-2 delta variant infection |
| title_fullStr | Doubtful clinical benefit of casirivimab-imdevimab treatment for disease severity outcome of high-risk patients with SARS-CoV-2 delta variant infection |
| title_full_unstemmed | Doubtful clinical benefit of casirivimab-imdevimab treatment for disease severity outcome of high-risk patients with SARS-CoV-2 delta variant infection |
| title_short | Doubtful clinical benefit of casirivimab-imdevimab treatment for disease severity outcome of high-risk patients with SARS-CoV-2 delta variant infection |
| title_sort | doubtful clinical benefit of casirivimab-imdevimab treatment for disease severity outcome of high-risk patients with sars-cov-2 delta variant infection |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8919793/ https://www.ncbi.nlm.nih.gov/pubmed/35300887 http://dx.doi.org/10.1016/j.ejim.2022.03.001 |
| work_keys_str_mv | AT shopennoah doubtfulclinicalbenefitofcasirivimabimdevimabtreatmentfordiseaseseverityoutcomeofhighriskpatientswithsarscov2deltavariantinfection AT dekelmichal doubtfulclinicalbenefitofcasirivimabimdevimabtreatmentfordiseaseseverityoutcomeofhighriskpatientswithsarscov2deltavariantinfection AT mizrahimichal doubtfulclinicalbenefitofcasirivimabimdevimabtreatmentfordiseaseseverityoutcomeofhighriskpatientswithsarscov2deltavariantinfection AT zandbergefrat doubtfulclinicalbenefitofcasirivimabimdevimabtreatmentfordiseaseseverityoutcomeofhighriskpatientswithsarscov2deltavariantinfection AT talmuddaniel doubtfulclinicalbenefitofcasirivimabimdevimabtreatmentfordiseaseseverityoutcomeofhighriskpatientswithsarscov2deltavariantinfection AT cohenneta doubtfulclinicalbenefitofcasirivimabimdevimabtreatmentfordiseaseseverityoutcomeofhighriskpatientswithsarscov2deltavariantinfection AT doubtfulclinicalbenefitofcasirivimabimdevimabtreatmentfordiseaseseverityoutcomeofhighriskpatientswithsarscov2deltavariantinfection |